Background and Objectives The clinical course and outcome of the Guillain-Barré syndrome
(GBS) are diverse and vary among regions. The modified Erasmus GBS Outcome Score
(mEGOS), developed with data from Dutch patients, is a clinical model that predicts the risk
of walking inability in patients with GBS. The study objective was to validate the mEGOS in
the International GBS Outcome Study (IGOS) cohort and to improve its performance and
region specificity. Methods We used prospective data from the first 1,500 patients included in …

Methods We used prospective data from the first 1,500 patients included in IGOS, aged≥ 6
years and unable to walk independently. We evaluated whether the mEGOS at entry and
week 1 could predict the inability to walk unaided at 4 and 26 weeks in the full cohort and in
regional subgroups, using 2 measures for model performance:(1) discrimination: area under
the receiver operating characteristic curve (AUC) and (2) calibration: observed vs predicted
probability of being unable to walk independently. To improve the model predictions, we …